May 15, 2024, 08:31 AM by

PLUTO’s embeddings will enable prediction of underlying molecular alterations driving cancer and disease phenotypes–including those previously hidden to AI–as well as the discovery of new biomarkers and therapeutic targets.

May 15, 2024, 08:31 AM by

May 15, 2024, 08:31 AM by

Optibrium’s AI-powered discovery platform Cerella™ chosen by FMC to accelerate its agrochemical discovery pipeline

May 15, 2024, 05:00 AM by User Not Found

Bio-IT World | Significant evidence now exists implicating the Epstein-Barr virus (EBV) as a causal factor in the development of multiple sclerosis (MS), making treatment of the virus a priority. To that end, research scientists at Trinity College Dublin have developed a blood test to measure the immune response to EBV that could be used as an outcome measure in future clinical trials in people with established MS.

May 14, 2024, 07:27 AM by

https://www.prnewswire.com/news-releases/fdb-expands-its-medication-instructions-to-include-translations-of-hindi--punjabi-2-of-the-fastest-growing-languages-in-the-us-302141989.html?tc=eml_cleartime

May 14, 2024, 07:27 AM by

Switchboard Health, creator of a high-value specialty care network and software platform, has secured $6.5 million in series seed funding.

May 14, 2024, 07:27 AM by

May 14, 2024, 07:27 AM by

Baylor Genetics, a clinical diagnostic laboratory at the forefront of genetic testing, today announced the availability of a new RNA sequencing test, RNAseq, for Whole Exome and Whole Genome Sequencing (WES/WGS). The company also reduced its standard turnaround time on WES and WGS to three weeks and continues to provide rapid testing with written reports in as few as five days.

May 14, 2024, 07:27 AM by

Watson-Marlow Fluid Technology Solutions (WMFTS) will showcase its recently launched DriveSure® panel mount pumps along with other products for life sciences companies at ACHEMA 2024 in Germany (June 10-14).

May 14, 2024, 07:27 AM by

May 14, 2024, 07:27 AM by

Built on the strong visions and values of the Trust, Guy’s and St Thomas’ “Together We Care” strategy centers on three primary priorities, Patients, People, and Partnerships, aiming to bolster patient autonomy, invest in staff, and harness technologies in collaboration with commercial partners. Guy’s and St Thomas’ implementation of PhenoTips’ Genomic Health Record on the final year of their 2018-2023 strategy completes the ambitious 5-year plan by empowering patients to take an active role in the collection of their data, streamlining staff and provider workflows, and establishing a framework for deep integration between the partner technologies supporting the Trust.

May 14, 2024, 05:00 AM by User Not Found

Bio-IT World | Using an artificial intelligence (AI) model that was trained on millions of variants from identified genetic disorders and incorporates the complex decision-making process of human molecular scientists, investigators at Baylor College of Medicine are on track to automate the diagnosis of an enormous number of undiagnosed conditions.

May 13, 2024, 08:37 AM by

The biotech startup Lactocore Group has reported unusual properties of a proprietary peptide, LCGA-17m16, aimed at treating neurological disorders without harming the heart that signal a potential paradigm shift in treating neurological disorders.

May 13, 2024, 08:37 AM by

Drug discovery specialist Cresset has announced a major milestone in its international growth with the launch of a new Indian HQ in Bangalore

May 13, 2024, 08:37 AM by

May 10, 2024, 07:37 AM by

May 10, 2024, 07:37 AM by

May 10, 2024, 07:37 AM by

ECI is thrilled to unveil its strategic rebranding, which combines Enhanced Compliance, Inc. and its Costa Rica-based subsidiary CRx Life Sciences into one entity and signals a critical juncture in the company’s ongoing growth and dedication to innovation in the life sciences industry. This fundamental transformation includes a refreshed brand identity, focusing on a refined brand structure and elevated visual appeal.

May 10, 2024, 07:37 AM by

May 10, 2024, 07:37 AM by

Josh brings extensive medical device, investment, and growth management experience to his new role.